<p>Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - 获取免费报告) 的股价在周二交易前跳涨。该股此前收于 18.33 美元，但开盘价为 19.39 美元。Kestra Medical Technologies 的股票最后交易价格为 19.0050 美元，成交量为 62,765 股。</p>
<h2>华尔街分析师观点</h2>
<p>几位研究分析师对该公司发布了报告。BTIG Research 在 3 月 25 日的研究报告中重申了 “买入” 评级，并将 Kestra Medical Technologies 的目标价设定为 32.00 美元。Stifel Nicolaus 在 12 月 12 日的研究报告中将 Kestra Medical Technologies 的目标价设定为 30.00 美元。Piper Sandler 在 12 月 12 日的报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 30.00 美元，并给予该公司 “增持” 评级。Wells Fargo &amp; Company 在 12 月 12 日的研究报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 28.00 美元，并给予该公司 “增持” 评级。最后，摩根士丹利在 1 月 16 日的研究报告中将 Kestra Medical Technologies 的目标价设定为 24.00 美元。三位研究分析师给予该股 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 28.80 美元。</p>
<p><strong>查看我们对 KMTS 的最新股票分析</strong></p>
<h2>Kestra Medical Technologies 股价上涨 3.2%</h2>
<p>该公司的债务与股本比率为 0.15，速动比率为 7.32，流动比率为 7.32。该公司的 50 日简单移动平均线为 23.58 美元，200 日简单移动平均线为 24.72 美元。该公司的市值为 11 亿美元，市盈率为-4.75。</p>
<p>Kestra Medical Technologies (NASDAQ:KMTS - 获取免费报告) 最近在 3 月 17 日宣布了其季度财报。该公司报告季度每股收益为（0.61 美元），低于市场共识预期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的净利润率为-171.87%，股本回报率为-65.49%。该公司季度收入为 2455 万美元，季度收入同比增长 62.7%。</p>
<h2>Kestra Medical Technologies 内部活动</h2>
<p>在其他消息中，内部人士 Brian Daniel Webster 在 3 月 17 日的交易中出售了 15,000 股该公司的股票。股票以平均价格 20.27 美元出售，总价值为 304,050.00 美元。出售完成后，内部人士持有该公司 364,786 股股票，价值约为 7,394,212.22 美元。这代表其持股比例减少了 3.95%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接访问。在过去三个月中，内部人士已出售价值 1,030,050 美元的 45,000 股公司股票。内部人士持有该公司 3.60% 的股份。</p>
<h2>对 Kestra Medical Technologies 的对冲基金观点</h2>
<p>大型投资者最近买入和卖出了该公司的股票。Farther Finance Advisors LLC 在第四季度购买了 Kestra Medical Technologies 的新股份，价值 31,000 美元。Russell Investments Group Ltd.在第四季度将其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.现在拥有 1,563 股该公司的股票，价值 41,000 美元，此前在此期间又购买了 474 股。China Universal Asset Management Co. Ltd.在第三季度购买了 Kestra Medical Technologies 的新股份，价值 48,000 美元。新泽西州警察和消防员退休系统在第二季度购买了 Kestra Medical Technologies 的新股份，价值 54,000 美元。最后，法国巴黎银行金融市场在第三季度将其在 Kestra Medical Technologies 的持股增加了 148.9%。法国巴黎银行金融市场现在拥有 2,738 股该公司的股票，价值 65,000 美元，此前在上个季度又购买了 1,638 股。</p>
<h2>Kestra Medical Technologies 公司简介</h2>
<p>(获取免费报告)</p>
<p>我们是一家商业阶段的可穿戴医疗设备和数字医疗公司，专注于通过直观、智能和互联的监测和治疗干预技术来改善心血管疾病患者的结果。我们开发并商业化了我们的心脏恢复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。我们心脏恢复系统平台的基石是 ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器（“WCD”），用于保护面临突发心脏骤停（“SCA”）风险的患者，这是一项重大公共卫生问题，占美国所有心血管死亡的约 50%。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Kestra Medical Technologies</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kestra Medical Technologies 吗？</h2>
<p>在你考虑投资 Kestra Medical Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kestra Medical Technologies 并不在名单上。</p>
<p>虽然 Kestra Medical Technologies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看五只股票</p>

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

KMTS

<p>Kestra Medical Technologies（纳斯达克代码：KMTS）股价在开盘前从 18.33 美元跳涨至 19.39 美元，最终收于 19.0050 美元。分析师的评级各不相同，BTIG Research 维持 “买入” 评级，目标价为 32.00 美元。该公司报告的季度每股收益为（0.61 美元），未达到预期，但收入同比增长 62.7%。内部交易方面，Brian Daniel Webster 出售了 15,000 股。该公司专注于心血管疾病的可穿戴医疗设备，市值为 11 亿美元，市盈率为-4.75</p>

<p>Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $18.33, but opened at $19.39. Kestra Medical Technologies shares last traded at $19.0050, with a volume of 62,765 shares traded.</p>
<div class="lb-trans"><p>Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - 获取免费报告) 的股价在周二交易前跳涨。该股此前收于 18.33 美元，但开盘价为 19.39 美元。Kestra Medical Technologies 的股票最后交易价格为 19.0050 美元，成交量为 62,765 股。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research analysts have issued reports on the company. BTIG Research restated a &#34;buy&#34; rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, March 25th. Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a research note on Friday, December 12th. Piper Sandler boosted their price objective on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, December 12th. Wells Fargo &amp; Company upped their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, December 12th. Finally, The Goldman Sachs Group set a $24.00 target price on Kestra Medical Technologies in a research note on Friday, January 16th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $28.80.</p>
<div class="lb-trans"><p>几位研究分析师对该公司发布了报告。BTIG Research 在 3 月 25 日的研究报告中重申了 “买入” 评级，并将 Kestra Medical Technologies 的目标价设定为 32.00 美元。Stifel Nicolaus 在 12 月 12 日的研究报告中将 Kestra Medical Technologies 的目标价设定为 30.00 美元。Piper Sandler 在 12 月 12 日的报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 30.00 美元，并给予该公司 “增持” 评级。Wells Fargo &amp; Company 在 12 月 12 日的研究报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 28.00 美元，并给予该公司 “增持” 评级。最后，摩根士丹利在 1 月 16 日的研究报告中将 Kestra Medical Technologies 的目标价设定为 24.00 美元。三位研究分析师给予该股 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 28.80 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on KMTS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 KMTS 的最新股票分析</strong></p>
</div><h2>Kestra Medical Technologies Stock Up 3.2%</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 股价上涨 3.2%</h2>
</div><p>The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The company has a fifty day simple moving average of $23.58 and a two-hundred day simple moving average of $24.72. The firm has a market capitalization of $1.10 billion and a PE ratio of -4.75.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.15，速动比率为 7.32，流动比率为 7.32。该公司的 50 日简单移动平均线为 23.58 美元，200 日简单移动平均线为 24.72 美元。该公司的市值为 11 亿美元，市盈率为-4.75。</p>
</div><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million for the quarter. The business's revenue for the quarter was up 62.7% on a year-over-year basis.</p>
<div class="lb-trans"><p>Kestra Medical Technologies (NASDAQ:KMTS - 获取免费报告) 最近在 3 月 17 日宣布了其季度财报。该公司报告季度每股收益为（0.61 美元），低于市场共识预期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的净利润率为-171.87%，股本回报率为-65.49%。该公司季度收入为 2455 万美元，季度收入同比增长 62.7%。</p>
</div><h2>Insider Activity at Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 内部活动</h2>
</div><p>In other news, insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the sale, the insider owned 364,786 shares of the company's stock, valued at approximately $7,394,212.22. This represents a 3.95% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 45,000 shares of company stock valued at $1,030,050. Insiders own 3.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Brian Daniel Webster 在 3 月 17 日的交易中出售了 15,000 股该公司的股票。股票以平均价格 20.27 美元出售，总价值为 304,050.00 美元。出售完成后，内部人士持有该公司 364,786 股股票，价值约为 7,394,212.22 美元。这代表其持股比例减少了 3.95%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接访问。在过去三个月中，内部人士已出售价值 1,030,050 美元的 45,000 股公司股票。内部人士持有该公司 3.60% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>对 Kestra Medical Technologies 的对冲基金观点</h2>
</div><p>Large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies during the fourth quarter worth $31,000. Russell Investments Group Ltd. increased its holdings in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after acquiring an additional 474 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Kestra Medical Technologies in the 3rd quarter worth $48,000. Police &amp; Firemen s Retirement System of New Jersey bought a new position in shares of Kestra Medical Technologies in the 2nd quarter worth $54,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。Farther Finance Advisors LLC 在第四季度购买了 Kestra Medical Technologies 的新股份，价值 31,000 美元。Russell Investments Group Ltd.在第四季度将其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.现在拥有 1,563 股该公司的股票，价值 41,000 美元，此前在此期间又购买了 474 股。China Universal Asset Management Co. Ltd.在第三季度购买了 Kestra Medical Technologies 的新股份，价值 48,000 美元。新泽西州警察和消防员退休系统在第二季度购买了 Kestra Medical Technologies 的新股份，价值 54,000 美元。最后，法国巴黎银行金融市场在第三季度将其在 Kestra Medical Technologies 的持股增加了 148.9%。法国巴黎银行金融市场现在拥有 2,738 股该公司的股票，价值 65,000 美元，此前在上个季度又购买了 1,638 股。</p>
</div><h2>Kestra Medical Technologies Company Profile</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p>
<div class="lb-trans"><p>我们是一家商业阶段的可穿戴医疗设备和数字医疗公司，专注于通过直观、智能和互联的监测和治疗干预技术来改善心血管疾病患者的结果。我们开发并商业化了我们的心脏恢复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。我们心脏恢复系统平台的基石是 ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器（“WCD”），用于保护面临突发心脏骤停（“SCA”）风险的患者，这是一项重大公共卫生问题，占美国所有心血管死亡的约 50%。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Kestra Medical Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Kestra Medical Technologies</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kestra Medical Technologies 吗？</h2>
</div><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Kestra Medical Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kestra Medical Technologies 并不在名单上。</p>
</div><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kestra Medical Technologies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

Kestra Medical Technologies (NASDAQ:KMTS) 股价跳空高开 - 是否仍然值得买入？